GLAXOSMITHKLINE PLC Form 6-K February 25, 2011

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For period ending February 2011

GlaxoSmithKline plc (Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No x

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

I give below details of changes in the interests of the under-mentioned person, a Person Discharging Managerial Responsibility, in the Ordinary Shares (ORDs) of GlaxoSmithKline plc as a result of awards made on 24 February 2011 as follows:

Award under	Ordinary shares
Mrs V A Whyte 2009 Share Value Plan	10,050
2009 Performance Share Plan	11,800

The 2009 Performance Share Plan award was made using an Ordinary Share price of £11.78, the closing price of Ordinary shares on 24 February 2011.

The Company and the Person Discharging Managerial Responsibility were advised of these transactions on 25 February 2011.

This notification relates to a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

V A Whyte Company Secretary

25 February 2011

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc (Registrant)

Date: February 25 2011

By: VICTORIA WHYTE

Victoria Whyte Authorised Signatory for and on

behalf of GlaxoSmithKline plc